Yes, tranexamic acid (TXA) should be administered to head injury patients, but with critical timing and severity-based considerations.
Administer TXA 1g IV bolus over 10 minutes followed by 1g over 8 hours to patients with traumatic brain injury (TBI) who are bleeding or at risk of significant bleeding, but ONLY within 3 hours of injury 1, 2. The benefit is most pronounced in mild to moderate TBI (GCS 9-15), while evidence suggests potential harm in isolated severe TBI (GCS 3-8).
Critical Decision Algorithm
When to Give TXA in Head Injury:
GIVE TXA if:
- Mild to moderate TBI (GCS 9-15) AND within 3 hours of injury 3
- Any TBI with signs of hemorrhagic shock (SBP <90 mmHg or HR >110 bpm) AND within 3 hours 1
- Treatment can be initiated within 2 hours for maximum benefit 4
DO NOT GIVE TXA if:
- Isolated severe TBI (GCS 3-8) without systemic bleeding 3, 5
- More than 3 hours post-injury (associated with INCREASED mortality risk) 1
- Subarachnoid hemorrhage (FDA contraindication due to cerebral edema/infarction risk) 6
Evidence-Based Rationale
The Time Window is Paramount
The CRASH-2 subgroup analysis definitively showed that TXA benefit disappears after 3 hours (RR 1.00 [0.86-1.17]) and administration beyond 3 hours actually increases hemorrhage-related death (RR 1.44 [1.12-1.84]) 1. Recent machine learning analysis of 28,448 trauma patients confirms optimal benefit within 2 hours, with rapidly decreasing effectiveness thereafter 4.
Severity Matters: The Divergent Evidence
The CRASH-3 trial (12,737 TBI patients) showed nuanced results: in patients treated within 3 hours, TXA reduced head injury-related death in mild-moderate TBI (RR 0.78 [0.64-0.95]) but showed no benefit in severe TBI (RR 0.99 [0.91-1.7]) 2. A 2025 meta-analysis of 15,015 patients confirms this pattern: TXA significantly reduced 28-day mortality in mild-moderate TBI (RR 0.71 [0.60-0.85]) but showed no benefit—and possible harm—in severe TBI (RR 1.05 [0.93-1.19]) 3.
The Exception: Severe TBI with Hemorrhagic Shock
Interestingly, combat casualty data suggests TXA may benefit severe head injuries when accompanied by severe overall injury (ISS ≥15) and hemorrhagic shock, with 25% lower mortality (OR 0.75 [0.59-0.95]) 7. This aligns with the principle that TXA's benefit relates to systemic hemorrhage control rather than isolated intracranial bleeding.
Practical Implementation
Standard Dosing:
Do NOT wait for viscoelastic testing (TEG/ROTEM) before administering TXA 2. Paradoxically, even patients with fibrinolytic shutdown on TEG showed mortality benefit from TXA (12% vs 24%, OR 0.36 [0.16-0.77]) 8, suggesting mechanisms beyond simple antifibrinolysis.
Critical Safety Considerations
Absolute Contraindications:
Thromboembolic Risk: The PATCH trial showed no increased thrombotic events at standard dosing (23.6% vs 19.7%, RR 1.20 [0.97-1.48]) 1. However, doses ≥4g show marked thromboembolic risk increase (HR 5.33 [1.94-14.63]) 9. Stick to the 2g total dose.
Common Pitfalls to Avoid
Don't delay for diagnostic certainty: The 2025 Anaesthesia guideline emphasizes TXA should not be restricted to documented severe injuries—clinical suspicion of significant bleeding is sufficient 1
Don't give late: Beyond 3 hours is harmful, not just ineffective 1
Don't use in isolated severe TBI without shock: Multiple studies show no benefit and potential harm 3, 5
Don't confuse with intracerebral hemorrhage (ICH): The neutral TICH-2 trial and ongoing TICH-3 trial address spontaneous ICH, not traumatic injury 10, 11
The evidence strongly supports early TXA in TBI with hemorrhage, particularly mild-moderate severity, administered within the critical 2-3 hour window. For isolated severe TBI without systemic bleeding, withhold TXA pending further evidence.